aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Rating of “Hold” from Brokerages

aTyr Pharma, Inc. (NASDAQ:ATYR) has been assigned a consensus recommendation of “Hold” from the seven analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $25.6667.

A number of brokerages recently issued reports on ATYR. Jefferies Financial Group reissued a “buy” rating on shares of aTyr Pharma in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th.

Hedge Funds Weigh In On aTyr Pharma

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in aTyr Pharma by 21.0% during the third quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock worth $4,060,000 after purchasing an additional 975,887 shares in the last quarter. UBS Group AG increased its position in shares of aTyr Pharma by 158.1% in the third quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock valued at $3,249,000 after buying an additional 2,760,238 shares in the last quarter. Octagon Capital Advisors LP raised its stake in shares of aTyr Pharma by 7.5% during the 2nd quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock worth $19,367,000 after buying an additional 268,000 shares during the period. GSA Capital Partners LLP raised its stake in shares of aTyr Pharma by 272.2% during the 4th quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock worth $2,060,000 after buying an additional 1,923,907 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of aTyr Pharma by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock valued at $1,789,000 after buying an additional 105,514 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

aTyr Pharma Trading Down 8.7%

aTyr Pharma stock traded down $0.08 during mid-day trading on Friday, hitting $0.82. The company had a trading volume of 1,749,790 shares, compared to its average volume of 1,496,836. aTyr Pharma has a 12-month low of $0.64 and a 12-month high of $7.29. The company’s fifty day moving average is $0.84 and its 200-day moving average is $1.43. The company has a market capitalization of $80.74 million, a price-to-earnings ratio of -1.04 and a beta of 0.55.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. As a group, sell-side analysts expect that aTyr Pharma will post -0.91 EPS for the current fiscal year.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.